News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Laboratory Corporation of America Holdings (LabCorp) (LH) Invests $2 Million in SynapDx Corporation


2/21/2013 9:26:29 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--SynapDx Corporation today announced it has secured $2 million in funding from Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH). This investment will support the clinical development of SynapDx’s breakthrough blood-based autism spectrum disorder (ASD) diagnostic test, designed to help clinicians identify children with autism earlier than they do today. This test will be the first step toward SynapDx’s building of a broader pediatric neurodevelopment testing offering. “LabCorp and SynapDx have a shared vision about the future of diagnostics,” said Stanley Lapidus, CEO, SynapDx. “The investment is validation of LabCorp’s commitment to innovation and SynapDx’s transformational approach to autism diagnostics.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES